{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', '6.4 SCREEN FAILURES', 'Screen failures are defined as participants who consent to participate in RECIPE but are not subsequently randomly', 'assigned to the study intervention or entered in the study. We will collect a minimal set of screen failure information to', 'ensure transparent reporting of screen failure participants, to meet the Consolidated Standards of Reporting Trials', '(CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information', 'includes demography, screen failure details, and eligibility criteria. Individuals who do not meet the criteria for', 'participation in this trial (screen failure) because of an abnormal lab value may be rescreened. Rescreened participants', 'will be assigned a new participant number, but will be documented in the system as a rescreen.', '6.5 STRATEGIES FOR RECRUITMENT AND RETENTION', 'Participant Recruitment', 'We will recruit and enroll 32 adults (> 18 years of age) whose signs and symptoms are inadequately controlled with', 'urate lowering therapy (e.g. xanthine oxidase inhibitors or uricosuric agents) at a medically appropriate dose or for', 'whom these drugs are contraindicated. Recruitment will include men and women of all races/ethnicities. Recruitment', 'will occur at UAB and UM. Patients will also be recruited directly from the UAB/UM hospitals and outpatient care', 'facilities (e.g. UAB/UM Rheumatology Clinics each seeing greater than 1000 gout patients per year). Advertisements will', 'be placed in the web page www.researchmatch.org, Birmingham/Ann Arbor metro area local newspapers, and UAB/UM', 'campus publications. The inclusion and exclusion criteria will be reviewed with all potential participants, and informed', 'consent will be obtained by the principal investigator, one of the co-investigators, or a trained member of the study', 'staff. Study procedures will not begin until signed informed consent has been obtained.', 'The study investigators and staff will have meetings bi-weekly to monitor site recruitment and to determine any', 'intervention for poor recruitment. In the event a problem is identified by either study site PI or staff, a', 'teleconference/webinar will be scheduled to review the issue. These teleconferences/webinars will include discussions', 'of overall recruitment status and identified barriers to recruitment experienced by the site with the study team', 'Participant Retention', 'During the screening and enrollment process, contact will be made with participants in a variety of ways (letters, staff', 'contact by phone and in person) for optimal retention. To increase retention, we hire engaging, attentive, and', 'responsive staff and who work with patients to provide flexible apt times where needed. The following major principals', 'and commonly used strategies to maximize retention and minimize loss to follow-up will be employed during the trial:', 'Stressing the idea that participants have an active role in the research and are part of the research team', \"Enhancing participant's understanding of the study's mission and the protocol\", 'Stressing that retention efforts begin with recruitment and are an ongoing process', 'Building participant relations and participant satisfaction, with the study staff taking a central role on this effort', 'Emphasizing the importance of congeniality, respectfulness and friendliness in interactions with participants', 'Actively discuss with participants any questions and concerns pertaining to their condition', 'Identifying potential problems and key retention factors, and developing intervention strategies regarding', 'retention', \"Assessing each participant's drop out potential and intervening as needed to keep participant interested in\", 'continuing to participate', 'In the event a study participant does not return for a study visit, then the site study staff will call to reschedule visit.', '7', 'STUDY INTERVENTION', '9']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', '7.1', 'STUDY INTERVENTION(S) ADMINISTRATION', '7.1.1 STUDY INTERVENTION DESCRIPTION OVERVIEW', 'Participants will be randomized 3:1 to either pegloticase + MMF (Peg+MMF) or to pegloticase + placebo (peg+PBO).', 'Experimental Arm:', 'Participants randomized to this arm will receive pegloticase + mycophenolate mofetil.', 'Drug: Mycophenolate Mofetil', 'Participants randomized to the pegloticase + MMF arm will start on 1) Pegloticase 8 mg intravenously (IV) every two', 'weeks, and 2) mycophenolate mofetil at 500 mg/BID and titrating up to 1000 mg/BID in 2 weeks if tolerated.', 'Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination', 'mycophenolate mofetil and pegloticase study period, participants will continue open-label pegloticase therapy for an', 'additional three months.', 'Drug: Pegloticase 8 mg/mL [Krystexxa]', 'Participants randomized to the pegloticase + MMF arm will start on 1) Pegloticase 8 mg IV every two weeks#, and 2)', 'mycophenolate mofetil at 500 mg/BID and titrating up to 1000 mg/BID in 2 weeks if tolerated. Mycophenolate mofetil', 'therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil', 'and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.', 'Other Name: Krystexxa', 'Placebo Comparator Arm:', 'Participants randomized to this arm will receive pegloticase + placebo', 'Drug: Placebo', 'Participants randomized to the pegloticase + placebo will receive placebo instead of mycophenolate mofetil therapy for', '12 weeks. After the 12-week combination placebo and pegloticase study period, participants will continue open label', 'pegloticase therapy for an additional three months.', 'Drug: Pegloticase 8 MG/ML [Krystexxa]', 'Participants randomized to the pegloticase + placebo will receive placebo instead of Mycophenolate mofetil therapy for', '12 weeks. After the 12-week combination placebo and pegloticase study period, participants will continue open label', 'pegloticase therapy for an additional three months.', 'Other Name: Krystexxa', '7.1.2 DOSING AND ADMINISTRATION OF STUDY DRUGS', 'Mycophenolate Mofetil (MMF)', 'Patients will be instructed that oral dosage tablets (250 mg over-encapsulated MMF or PBO) will be administered on an', 'empty stomach (1 hour before or 2 hours after meals) to avoid variability in Moiety Mycophenolic Acid (MPA)', 'absorption. If a dose is missed, it will be administered as soon as it is remembered. If it is close to the next scheduled', 'dose, the participant will be instructed to skip the missed dose and resume at the next regularly scheduled time; thus,', 'participants will be instructed not to double a dose to make up for a missed dose.', '10']\n\n###\n\n", "completion": "END"}